Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, have established a research collaboration with Memory Treatment Centers. Working with Dr Don McCarren (DO, FAAN, FAANEM) and Dr Jamie Plante (MD).
OBD will investigate cortical microstructural disarray in subjects who are cognitively impaired and receiving an anti-amyloid treatment.
Dr Steven Chance, CEO, Co-founder, (PhD) Oxford Brain Diagnostics said ‘we are very pleased to be working with Don, Jamie, and the team at MTC. OBD is fully committed to this collaboration, and we very much look forward to unlocking the power of microstructure and sharing the insights from this project as part of our engagement with MTC. Our goal is to continue to push the research boundaries of Alzheimer’s disease and showcase the insights that CDM offers in answering the difficult and challenging questions patients face in the real world. Access to vital partnerships like the one with MTC will enable further insights into discovering the important role cortical microstructure plays in a clinical setting.’
Dr Don McCarren, Memory Treatment Centers, said, “We at MTC are excited to collaborate with Oxford Brain Diagnostics and contribute to innovation and advancement of patient care. This partnership allows us to contribute HIPAA-compliant, real-world data to the global neurologic community and advance our understanding of the disease and its treatment.”
Founded in neuropathological and neuroimaging expertise, Oxford Brain Diagnostics Ltd’s Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases.
The company is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.
Memory Treatment Centers specialise in innovative treatments and advancing the level and effectiveness of memory diagnosing, treatment, and monitoring. The company actively pursue new treatment opportunities and partnerships to enhance memory care and expand patient access to treatment.